The existence of specific angiogenesis inhibitors was first postulated by Folkman in 1971 in an editorial (Folkman 1971). In this paper, Folkman wrote that: “it seems appropriate to speculate that ‘anti-angiogenesis’ may provide a form of cancer therapy worthy os serious exploration. One approach to the initiation of ‘anti-angiogenesis’ would be the production of an antibody against TAF; such an attempt is under way in our laboratory (…) Anti-angiogenesis may become a powerful adjunct to present methods of cancer therapy. If ‘anti-angiogenesis’ is not possible, or even if the concept is wrong, the careful exploration of its consequences may reveal something fundamental about the behavior of tumor cells growing in a packed population in vivo.” (Folkman 1971). Moreover: “It is tempting to suggest that tumor growth might be arrested at a very small size if the anti-angiogenesis activity of this factor could be blocked. This would be analogous to the cessation of growth of bacterial colonies when their size exceeds the diffusion of nutrients.” (Folkman et al. 1971).
- Cooke R (2001) Dr. Folkman’s war. Angiogenesis and the struggle to defeat cancer. Random House, New YorkGoogle Scholar
- Folkman J (1998a) New directions in angiogenesis research (Abstr 031). 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, June 16–19, 1998, AmsterdamGoogle Scholar
- Folkman J (2008) Tumor angiogenesis: from bench to bedside. In: Marmé D, Fusenig N (eds) Tumor angiogenesis. Basic mechanisms nad cancer therapy. Springer-Verlag, Heidelberg, pp 3–28Google Scholar
- Relf M, Le Jeune S, Fox S et al (1997) Expression of the angiogenic factors vascular endothelial growth factor acidic and basic fibroblast growth factor, transforming growth factor-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963–969PubMedGoogle Scholar